Iovance Biotherapeutics, Inc. (IOVA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Core Insights - Iovance Therapeutics is focusing on three key pillars of strength for growth in 2026 and beyond [2][3] Group 1: Commercial Business - The U.S. commercial business is driven by the product Amtagvi, which is approved for previously treated advanced melanoma and has a peak sales potential of at least $1 billion in the U.S. [2] Group 2: Pipeline Development - The company is building a pipeline that serves as the backbone of immuno-oncology in solid tumors, with a lead program in advanced non-small cell lung cancer that has a potential best-in-class profile [3] Group 3: Operational Excellence - Iovance is focusing on operational excellence by growing revenue, reducing expenses, and realizing efficiencies on its path to profitability [3]